Molecule ChEMBL ID,Molecule Name,Molecule Max Phase,Molecular Weight,#RO5 Violations,AlogP,Compound Key,Smiles,Standard Type,Standard Relation,Standard Value,Standard Units,pChEMBL Value,Data Validity Comment,Comment,Uo Units,Ligand Efficiency BEI,Ligand Efficiency LE,Ligand Efficiency LLE,Ligand Efficiency SEI,Potential Duplicate,Assay ChEMBL ID,Assay Description,Assay Type,BAO Format ID,BAO Label,Assay Organism,Assay Tissue ChEMBL ID,Assay Tissue Name,Assay Cell Type,Assay Subcellular Fraction,Assay Parameters,Assay Variant Accession,Assay Variant Mutation,Target ChEMBL ID,Target Name,Target Organism,Target Type,Document ChEMBL ID,Source ID,Source Description,Document Journal,Document Year,Cell ChEMBL ID,Properties,Action Type,Standard Text Value,Bioactivities
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Tmax,'=',2.7,hr,,,,UO_0000032,,,,,0,CHEMBL4825933,"Tmax in Sprague-Dawley rat at 10 mg/kg, po measured after 0.02 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,2.7
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',79,%,,,,UO_0000187,,,,,0,CHEMBL4825957,"Antiviral activity against Respiratory syncytial virus A2 infected in Balb/C mouse assessed as reduction in viral titers in lung homogenates at 1 mg/kg, po treated 2 hrs prior to viral infection followed by compound redosing at 24 hrs and measured after 5 days post infection by plaque assay relative to control",F,BAO_0000218,organism-based format,Human respiratory syncytial virus,CHEMBL3638235,Lung,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 1.0 mg.kg-1 | TIME = 2.0 hr,,,79
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,EC50,'=',3.4,nM,8.47,,,UO_0000065,,,,,0,CHEMBL4739816,Effect on Wnt signaling pathway in human SW480 cells harbouring TCF/LEF luciferase reporter gene and SP5-Luc reporter gene incubated for 36 to 48 hrs by luminescence assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,SW480,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,Time_Lower = 36.0 hrs | Time_Upper = 48.0 hrs,INHIBITOR,,0.0034
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Emax,'=',397.03,%,,,,UO_0000187,,,,,0,CHEMBL4739814,Induction of chondrogenesis in human MSC assessed as maximum activity at 30 nM incubated for 6 days by rhodamine B and Nile red staining based imaging analysis relative to control,F,BAO_0000221,tissue-based format,Homo sapiens,None,None,BMMSC,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,Dose = 30.0 nM | TIME = 144.0 hr,,,397.03
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Fu,'=',0.044,,,,,,,,,,0,CHEMBL3413803,Percentage unbound in human plasma at 2 uM by equilibrium dialysis,A,BAO_0000366,cell-free format,Homo sapiens,CHEMBL3559721,Plasma,None,None,,,,CHEMBL613424,Plasma,Homo sapiens,TISSUE,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,4.4
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,T1/2,'=',8.9,hr,,,,UO_0000032,,,,,0,CHEMBL3413816,Terminal half life in po dosed beagle dog,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL373,Canis familiaris,Canis lupus familiaris,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,8.9
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Activity,'>',99.9,%,,,,UO_0000187,,,,,0,CHEMBL3411895,"Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in absolute viral load AUC at 50 mg, po as loading dose followed by 25 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post infection measured up to day 12 post infection relative to placebo",F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,99.9
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Activity,'=',38,%,,,,UO_0000187,,,,,0,CHEMBL3411997,"Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in log10 viral load AUC at 10 mg, po as loading dose followed by 5 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post infection measured up to day 12 post infection relative to placebo",F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,38
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Activity,,,,,,Dose-dependent effect,,,,,,0,CHEMBL3411998,Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in log10 viral load AUC compound dosed po starting on days 2 to 5 post infection for total 5 days measured up to day 12 post infection relative to placebo,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.44,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 12.86 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 24.0 hours,,,-0.44
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.03,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 21.97 % | Growth Rate in DMSO (control) = 1.06 None | Replicate number = 2.0 None | Timepoint = 12.0 hours,,,-0.03
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.94,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 20.64 % | Growth Rate in DMSO (control) = 1.91 None | Replicate number = 2.0 None | Timepoint = 0.0 hours,,,-0.94
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Activity,'=',13.78,nM,,,,UO_0000065,,,,,0,CHEMBL4739828,Inhibition of IL1-beta induced MMP1 expression levels in human chondrocytes assessed as MMP1 levels incubated for 2hrs followed by IL1-beta stimulation and measured after 24 hrs by qRT-PCR analysis,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Chondrocyte,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 26.0 hr,,,13.78
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,7-2; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',1.3,nM,8.89,,,UO_0000065,,,,,0,CHEMBL4376915,Antiviral activity against Respiratory syncytial virus,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,1.3
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.37,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 15.83 % | Growth Rate in DMSO (control) = 1.03 None | Replicate number = 2.0 None | Timepoint = 18.0 hours,,,-0.37
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',237.7,nM,6.62,,,UO_0000065,13.1,0.24,0.27,5.9,0,CHEMBL5251368,Inhibition of recombinant human CLK4 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4203,Dual specificity protein kinase CLK4,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.2377
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,COVC-2819596058,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,IC50,'>',19952.62,nM,,,No. Measurements = 1,UO_0000065,,,,,0,CHEMBL4651403,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4651402,57,IMI-CARE SARS-CoV-2 Data,,2021,CHEMBL4295411,,,,4.7
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,COVC-2819596058,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,IC50,'>',20000,nM,,,No. Measurements = 1,UO_0000065,,,,,0,CHEMBL4651403,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4651402,57,IMI-CARE SARS-CoV-2 Data,,2021,CHEMBL4295411,,,,0.00002
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',14.18,nM,7.85,,,UO_0000065,,,,,0,CHEMBL3603640,Growth inhibition of human H296R cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,H296R,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,0.01418
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL3603654,Inhibition of NFkappaB in human STF cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.67,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.27 % | Growth Rate in DMSO (control) = 1.02 None | Replicate number = 1.0 None | Timepoint = 18.0 hours,,,-0.67
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'<',10,nM,,,,UO_0000065,,,,,0,CHEMBL3603631,Inhibition of Wnt/beta-catenin (unknown origin),B,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,10
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Activity,'=',67,%,,,,UO_0000187,,,,,0,CHEMBL3411894,"Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in log10 viral load AUC at 50 mg, po as loading dose followed by 25 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post infection measured up to day 12 post infection relative to placebo",F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,67
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,T1/2,'=',3.4,hr,,,,UO_0000032,,,,,0,CHEMBL3413815,Terminal half life in po dosed Sprague-Dawley rat,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,3.4
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.16,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 19.46 % | Growth Rate in DMSO (control) = 1.04 None | Replicate number = 2.0 None | Timepoint = 6.0 hours,,,-0.16
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',5620,nM,5.25,,,UO_0000065,,,,,0,CHEMBL3603637,Inhibition of CYP2C9 (unknown origin),A,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL3397,Cytochrome P450 2C9,Homo sapiens,SINGLE PROTEIN,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,5.62
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',80.78,nM,7.09,,,UO_0000065,,,,,0,CHEMBL3603642,Growth inhibition of human MCF7 cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,MCF7,None,,,,CHEMBL387,MCF7,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3308403,,,,0.08078
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603648,Inhibition of thyroid hormone receptor in human STF cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL2111462,Thyroid hormone receptor,Homo sapiens,PROTEIN COMPLEX,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Fu,'=',0.27,,,,,,,,,,0,CHEMBL4825892,Protein binding in dog plasma assessed as unbound fraction at 5 uM by LC-MS/MS analysis based equilibrium dialysis method,A,BAO_0000366,cell-free format,Canis lupus familiaris,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 5.0 microM,,,27
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CLH,'=',17,uL/min,,,,UO_0000271,,,,,0,CHEMBL4825894,Intrinsic clearance in Sprague-Dawley rat liver microsomes preincubated followed by NADPH addition and measured up to 45 mins by LC-MS/MS analysis,A,BAO_0000251,microsome format,Rattus norvegicus,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,TIME: <=45,,,17
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',530.5,nM,6.28,,,UO_0000065,,,,,0,CHEMBL3603662,Cytotoxicity against human ovarian cancer cell aggregates grown on matrigel incubated for 72 hrs by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Cancer cell lines,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307923,,,,0.5305
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.52,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 13.2 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 18.0 hours,,,-0.52
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.98,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 14.81 % | Growth Rate in DMSO (control) = 2.19 None | Replicate number = 2.0 None | Timepoint = 6.0 hours,,,-0.98
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',1.3,nM,8.89,,,UO_0000065,,,,,0,CHEMBL4825887,Antiviral activity against Respiratory syncytial virus A2 infected in African green monkey Vero cells by Plaque reduction assay,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,Vero,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,1.3
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',9.9,hr,,,,UO_0000032,,,,,0,CHEMBL4825928,"Half life in CD1 mouse at 10 mg/kg, po measured after 0.083 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | Time_Lower = 0.083 hrs | Time_Upper = 24.0 hrs,,,9.9
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',5.9,hr,,,,UO_0000032,,,,,0,CHEMBL4825930,"Half life in Sprague-Dawley rat at 50 mg/kg, po measured after 0.02 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,5.9
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CL,'=',17.8,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4825941,"Clearance in Beagle dog at 0.3 mg/kg, iv measured after 0.03 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 0.3 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,17.8
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',44.2,%,,,,UO_0000187,,,,,0,CHEMBL4825944,Oral bioavailability in Beagle dog at 3 mg/kg measured after 0.03 to 24 hrs by UHPLC-TOF method,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 3.0 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,44.2
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Non-Toxic,,,,,,0,CHEMBL4825952,Cytotoxicity against human airway epithelial cells assessed as change in cell viability at 10 nM preincubated for 2 hrs followed by viral infection and measured after 8 day post infection by H and E staining based assay,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HAE,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 10.0 nM | TIME = 2.0 hr,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Toxic,,,,,,0,CHEMBL4825958,Cardiotoxicity in guinea pig assessed as effect on QT interval,T,BAO_0000019,assay format,Cavia porcellus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CL,'=',164,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4825972,"Clearance in Sprague-Dawley rat at 50 mg/kg, po measured after 0.25 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | Time_Lower = 0.25 hrs | Time_Upper = 24.0 hrs,,,164
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (acute),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137724,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (successful reintroduction),,,,,,,,,,,,0,CHEMBL3137737,Presence of at least one case with successful reintroduction. [column 'REINT' in source],T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (comment),,,,,,,,,,,,0,CHEMBL3137738,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,GI50,'=',90,nM,,,,UO_0000065,,,,,0,CHEMBL3603632,Growth inhibition of human HT-29 cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,HT-29,None,,,,CHEMBL384,HT-29,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307768,,,,0.09
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,LogD,'=',3.3,,,,,,,,,,0,CHEMBL3603634,"Lipophilicity, log D of the compound",P,BAO_0000100,small-molecule physicochemical format,None,None,None,None,None,,,,CHEMBL2362975,No relevant target,,NO TARGET,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,3.3
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Activity,,,,,,Dose-dependent effect,,,,,,0,CHEMBL3603673,Induction of apoptosis in human colon cancer cells incubated for 48 to 72 hrs by annexin V-FITC and propidium iodide staining based flow cytometry,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Cancer cell lines,None,,,,CHEMBL614375,Cancer cell lines,,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307923,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,CL,'=',32.17,mL.min-1.kg-1,,,,,,,,,0,CHEMBL3413809,"Clearance in Sprague-Dawley rat at 1 mg/kg, iv administered as infusion over 30 mins",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,1.93
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Cmax,'=',501.74,nM,,,standard_value was converted from ug.mL-1 to nM using the parent compound MW,UO_0000065,,,,,0,CHEMBL4825937,"Cmax in CD1 mouse at 10 mg/kg, po measured after 0.083 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | ROUTE: ORAL | Time_Lower = 0.083 hrs | Time_Upper = 24.0 hrs,,,224
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Cmax,'=',166.2,nM,,,standard_value was converted from ug.mL-1 to nM using the parent compound MW,UO_0000065,,,,,0,CHEMBL4825938,"Cmax in Sprague-Dawley rat at 10 mg/kg, po measured after 0.02 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | ROUTE: ORAL | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,74.2
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Cmax,'=',184.57,nM,,,standard_value was converted from ug.mL-1 to nM using the parent compound MW,UO_0000065,,,,,0,CHEMBL4825940,"Cmax in Beagle dog at 3 mg/kg, po measured after 0.03 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 3.0 mg.kg-1 | ROUTE: ORAL | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,82.4
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (cirrhosis),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137730,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,permeability,'=',6.4,10'-6 cm/s,,,,,,,,,0,CHEMBL3413801,Permeability from apical to basolateral side of human Caco2 cells at 10 uM by LC/MS/MS analysis,A,BAO_0000219,cell-based format,Homo sapiens,None,None,Caco-2,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,CHEMBL3307519,,,,6.4
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,Presatovir,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Inhibition,'=',7.442,%,,,,UO_0000187,,,,,0,CHEMBL4495582,SARS-CoV-2 3CL-Pro protease inhibition percentage at 20ÂµM  by FRET kind of response from peptide substrate,F,BAO_0000019,assay format,Severe acute respiratory syndrome coronavirus 2,None,None,None,None,,,,CHEMBL4523582,Replicase polyprotein 1ab,Severe acute respiratory syndrome coronavirus 2,SINGLE PROTEIN,CHEMBL4495564,52,SARS-CoV-2 Screening Data,,2020,None,,,,7.441795087
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Solubility,'=',1,ug.mL-1,,,,UO_0000274,,,,,0,CHEMBL3603635,Solubility of the compound,P,BAO_0000100,small-molecule physicochemical format,None,None,None,None,None,,,,CHEMBL2362975,No relevant target,,NO TARGET,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,1
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Activity,,,,,,Active,,,,,,0,CHEMBL3603674,Induction of apoptosis in HEK293 cells transfected with Wnt3A at 10 uM by propidium iodide staining based flow cytometry,F,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK293,None,,,,CHEMBL614818,HEK293,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307715,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,F,'=',130,%,,,,UO_0000187,,,,,0,CHEMBL3413819,Oral bioavailability in beagle dog at 4 mg/kg,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL373,Canis familiaris,Canis lupus familiaris,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,130
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Ratio,'=',10,,,,,,,,,,0,CHEMBL3413825,"Ratio of AUC (0 to 12 hrs) in epithelial lining fluid to AUC (0 to 12 hrs) in plasma of Sprague-Dawley rat at 1 mg/kg, iv",A,BAO_0000218,organism-based format,Rattus norvegicus,CHEMBL3559721,Plasma,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,10
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL3603655,Inhibition of NFkappaB in human STF3A cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Activity,,,,,,Non-toxic,,,,,,0,CHEMBL3603666,"Toxicity in human SW480 cells xenografted nu/nu mouse assessed as change in body weight at 35 mg/kg, po administered every 5 days per week for 3 weeks",T,BAO_0000218,organism-based format,Mus musculus,None,None,SW480,None,,,,CHEMBL375,Mus musculus,Mus musculus,ORGANISM,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307758,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CC50,'>',4000,nM,,,,UO_0000065,,,,,0,CHEMBL4825888,Cytotoxicity against African green monkey Vero cells by MTT assay,A,BAO_0000219,cell-based format,Chlorocebus sabaeus,None,None,Vero,None,,,,CHEMBL391,Vero,Chlorocebus sabaeus,CELL-LINE,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3307520,,,,4000
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CLH,'=',44,uL/min,,,,UO_0000271,,,,,0,CHEMBL4825896,Intrinsic clearance in human liver microsomes preincubated followed by NADPH addition and measured up to 45 mins by LC-MS/MS analysis,A,BAO_0000251,microsome format,Homo sapiens,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,TIME: <=45,,,44
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',102,%,,,,UO_0000187,,,,,0,CHEMBL4825915,Oral bioavailability in Sprague-Dawley rat at 10 mg/kg administered via gavage measured after 0.02 to 24 hrs by tandem liquid chromatography/mass spectrometry,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,102
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',76.42,%,,,,UO_0000187,,,,,0,CHEMBL4825965,Antiviral activity against Respiratory syncytial virus A Memphis 37b infected in human assessed as reduction in mean AUC of viral load at 200 mg administered twice daily administered for 5 days by cell-based infectivity assay,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 200.0 mg | TIME = 120.0 hr,,,76.42
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Active,,,,,,0,CHEMBL4825966,Antiviral activity against Respiratory syncytial virus A Memphis 37b infected in human assessed as reduction in nasal mucus weight at 200 to 350 mg administered twice daily administered for 5 days,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose_Lower = 200.0 mg | Dose_Upper = 350.0 mg | TIME = 120.0 hr,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,GI,,,,,,Active,,,,,,0,CHEMBL3603667,Cytotoxicity against human HCT15 cell aggregates grown on matrigel incubated for 5 to 8 days by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,HCT-15,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307945,,,,
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (moderate),'=',1,,,,references out of a total of 1,,,,,,0,CHEMBL3137722,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,1
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CL,'=',164,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4825913,"Clearance in Sprague-Dawley rat at 1 mg/kg, iv administered via gavage measured after 0.02 to 24 hrs by tandem liquid chromatography/mass spectrometry",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 1.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,164
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',1.55,hr,,,,UO_0000032,,,,,0,CHEMBL4825919,Half life in rat hepatocytes at 3 uM measured up to 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Rattus norvegicus,None,None,Hepatocyte,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3308027,Dose = 3.0 microM | TIME: <=60,,,93
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,log(activity),'=',2.3,,,,,,,,,,0,CHEMBL4825948,Antiviral activity against Respiratory syncytial virus infected in human airway epithelial cells assessed as reduction in RSV titer at 10 nM preincubated for 2 hrs followed by viral infection and measured after 7 day post infection by luminescence assay relative to control,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HAE,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 10.0 nM | TIME = 2.0 hr,,,2.3
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Toxic,,,,,,0,CHEMBL4825969,Induction of adverse effect in human infected with Respiratory syncytial virus A Memphis 37b assessed as diarrhea at 200 to 350 mg administered twice daily administered for 5 days,A,BAO_0000019,assay format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose_Lower = 200.0 mg | Dose_Upper = 350.0 mg | TIME = 120.0 hr,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Ratio,'=',22,,,,,,,,,,0,CHEMBL3413804,"Fold plasma shift, ratio of fraction unbound in culture media/buffer to fraction unbound in human plasma",A,BAO_0000019,assay format,None,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,22
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.36,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 27.19 % | Growth Rate in DMSO (control) = 1.03 None | Replicate number = 1.0 None | Timepoint = 12.0 hours,,,0.36
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.41,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 7.47 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 24.0 hours,,,-0.41
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.68,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 14.54 % | Growth Rate in DMSO (control) = 1.09 None | Replicate number = 2.0 None | Timepoint = 12.0 hours,,,-0.68
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,Presatovir,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Inhibition,'=',-2.52,%,,,,UO_0000187,,,,,0,CHEMBL4808150,Enzymatic assay of human HDAC6 with custom peptide substrate,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL1865,Histone deacetylase 6,Homo sapiens,SINGLE PROTEIN,CHEMBL4808148,59,Fraunhofer Institute HDAC6 screening,,2021,None,,,,-2.52
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.2,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 24.52 % | Growth Rate in DMSO (control) = 1.11 None | Replicate number = 1.0 None | Timepoint = 6.0 hours,,,-0.2
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,LogD,'=',2,,,,,,,,,,0,CHEMBL3413800,"Lipophilicity, log D of the compound by chromatography",P,BAO_0000100,small-molecule physicochemical format,None,None,None,None,None,,,,CHEMBL2362975,No relevant target,,NO TARGET,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,2
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CLH,'=',14.8,uL/min,,,,UO_0000271,,,,,0,CHEMBL4825916,Intrinsic clearance in rat hepatocytes at 3 uM assessed per million cells measured up to 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Rattus norvegicus,None,None,Hepatocyte,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3308027,Dose = 3.0 microM | TIME: <=60,,,14.8
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CLH,'=',2.4,uL/min,,,,UO_0000271,,,,,0,CHEMBL4825917,Intrinsic clearance in Beagle dog hepatocytes at 3 uM assessed per million cells measured up to 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Canis lupus familiaris,None,None,Hepatocyte,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3308583,Dose = 3.0 microM | TIME: <=60,,,2.4
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-1.68,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5063731,Thermal Shift Assay. Domain: start/stop: M1-K294,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHSSGVDLGTENLYFQSMMELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK | Refseq Start/Stop: M1-K294,,,CHEMBL2828,Casein kinase I delta,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-1.68
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-1,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 12.62 % | Growth Rate in DMSO (control) = 151.07 None | Replicate number = 1.0 None | Timepoint = 6.0 hours,,,-1
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Tmax,'=',4,hr,,,,UO_0000032,,,,,0,CHEMBL4825935,"Tmax in Beagle dog at 3 mg/kg, po measured after 0.03 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 3.0 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,4
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603636,Inhibition of human ERG,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL240,HERG,Homo sapiens,SINGLE PROTEIN,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',30.57,nM,7.51,,,UO_0000065,,,,,0,CHEMBL3603643,Growth inhibition of human HCT15 cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,HCT-15,None,,,,CHEMBL612263,HCT-15,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307945,,,,0.03057
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603646,Inhibition of STAT3 in human STF cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL4026,Signal transducer and activator of transcription 3,Homo sapiens,SINGLE PROTEIN,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603649,Inhibition of thyroid hormone receptor in human STF3A cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL2111462,Thyroid hormone receptor,Homo sapiens,PROTEIN COMPLEX,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603651,Inhibition of RXR in human STF cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL2363070,Retinoid X receptor,Homo sapiens,PROTEIN FAMILY,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603652,Inhibition of RAR in human STF3A cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL2363069,Retinoic acid receptor,Homo sapiens,PROTEIN FAMILY,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',34.2,nM,7.47,,,UO_0000065,,,,,0,CHEMBL3603664,Cytotoxicity against human H296R cell aggregates grown on matrigel incubated for 72 hrs by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,H296R,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,0.0342
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',2.05,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5062802,Thermal Shift Assay. Domain: start/stop: M1-L298,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHSSGVDLGTENLYFQSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL | Refseq Start/Stop: M1-L298,,,CHEMBL301,Cyclin-dependent kinase 2,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,2.05
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-0.78,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5064660,Thermal Shift Assay. Domain: start/stop: P449-E759,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHSSGVDLGTENLYFQSMPTLANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTSKPPEEQLTFKDLVSCAYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKETTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMREXWHAAPSQRPTFKQLVEDLDRVLTVTSTDE | Refseq Start/Stop: P449-E759,,,CHEMBL2742,Fibroblast growth factor receptor 3,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-0.78
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,TGI,,,,,,Active,,,,,,0,CHEMBL3603665,"Antitumor activity against human SW480 cells xenografted in nu/nu mouse assessed as tumor growth inhibition at 35 mg/kg, po administered every 5 days per week for 3 weeks",F,BAO_0000218,organism-based format,Homo sapiens,None,None,SW480,None,,,,CHEMBL612544,SW480,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307758,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,CL,'=',3.833,mL.min-1.kg-1,,,,,,,,,0,CHEMBL3413810,"Clearance in beagle dog at 1 mg/kg, iv administered as infusion over 30 mins",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL373,Canis familiaris,Canis lupus familiaris,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,0.23
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Vdss,'=',4.95,L.kg-1,,,,UO_0000197,,,,,0,CHEMBL3413814,Volume of distribution at steady state in cynomolgus monkey,A,BAO_0000218,organism-based format,Macaca fascicularis,None,None,None,None,,,,CHEMBL613847,Cynomolgus monkey,Macaca fascicularis,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,4.95
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Activity,,,,,,Dose-dependent effect,,,,,,0,CHEMBL3413947,Antiviral activity against Respiratory syncytial virus infected in cotton rat assessed as reduction in viral RNA level in lung tissue administered ip 1 hr prior infection measured on day 4 by RT-qPCR analysis,F,BAO_0000218,organism-based format,Respiratory syncytial virus,CHEMBL3638235,Lung,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CL,'=',47.9,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4825901,"Clearance in CD1 mouse at 1 mg/kg, iv measured after 0.083 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 1.0 mg.kg-1 | Time_Lower = 0.083 hrs | Time_Upper = 24.0 hrs,,,47.9
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',12.3,hr,,,,UO_0000032,,,,,0,CHEMBL4825927,"Half life in Beagle dog at 0.3 mg/kg, iv measured after 0.03 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 0.3 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,12.3
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',1.18,nM,8.93,,,UO_0000065,,,,,0,CHEMBL4825954,Antiviral activity against Respiratory syncytial virus Memphis 37b infected in human HEp2 cells by plaque assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HEp-2,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,1.18
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,CC50,'>',20000,nM,,,,UO_0000065,,,,,0,CHEMBL3413806,Cytotoxicity against human MT4 cells,A,BAO_0000219,cell-based format,Homo sapiens,None,None,MT4,None,,,,CHEMBL388,MT4,Homo sapiens,CELL-LINE,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,CHEMBL3308375,,,,20
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Vdss,'=',9.75,L.kg-1,,,,UO_0000197,,,,,0,CHEMBL3413812,Volume of distribution at steady state in Sprague-Dawley rat,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,9.75
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Cmax,'=',166.2,nM,,,standard_value was converted from ug.mL-1 to nM using the parent compound MW,UO_0000065,,,,,0,CHEMBL4825912,"Cmax in Sprague-Dawley rat at 5 mg/kg, po administered via gavage measured after 0.02 to 24 hrs by tandem liquid chromatography/mass spectrometry",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 5.0 mg.kg-1 | ROUTE: ORAL | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,74.2
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',9.667,hr,,,,UO_0000032,,,,,0,CHEMBL4825920,Half life in Beagle dog hepatocytes at 3 uM assessed per million cells measured up to 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Canis lupus familiaris,None,None,Hepatocyte,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3308583,Dose = 3.0 microM | TIME: <=60,,,580
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',63.05,%,,,,UO_0000187,,,,,0,CHEMBL4825964,Antiviral activity against Respiratory syncytial virus A Memphis 37b infected in human assessed as reduction in mean AUC of viral load at 350 mg administered twice daily administered for 5 days by RT-qPCR analysis,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 350.0 mg | TIME = 120.0 hr,,,63.05
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Toxic,,,,,,0,CHEMBL4825968,Induction of adverse effect in human infected with Respiratory syncytial virus A Memphis 37b assessed as nausea at 200 to 350 mg administered twice daily administered for 5 days,A,BAO_0000019,assay format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose_Lower = 200.0 mg | Dose_Upper = 350.0 mg | TIME = 120.0 hr,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',68.6,%,,,,UO_0000187,,,,,0,CHEMBL4825971,Antiviral activity against Respiratory syncytial virus A Memphis 37b infected in human assessed as reduction in mean AUC of viral load at 350 mg administered twice daily administered for 5 days by cell-based infectivity assay,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 350.0 mg | TIME = 120.0 hr,,,68.6
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Fu,'=',0.67,,,,,,,,,,0,CHEMBL4825893,Protein binding in human plasma assessed as unbound fraction at 5 uM by LC-MS/MS analysis based equilibrium dialysis method,A,BAO_0000366,cell-free format,Homo sapiens,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 5.0 microM,,,67
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Papp,'=',0.5,10^-6 cm/s,,,,,,,,,0,CHEMBL4825908,Apparent permeability across apical to basolateral side in MDCK-MDR1 cells at 10 uM measured at 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Canis lupus familiaris,None,None,MDCK-MDR1,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL4295482,Dose = 10.0 microM | TIME = 1.0 hr,,,0.5
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',98,%,,,,UO_0000187,,,,,0,CHEMBL4825886,"Antiviral activity against Respiratory syncytial virus A2 infected in Balb/C mouse assessed as reduction in viral titers in lung homogenates at 50 mg/kg, po treated 2 hrs prior to viral infection followed by compound redosing at 24 hrs and measured after 5 days post infection by plaque assay relative to control",F,BAO_0000218,organism-based format,Human respiratory syncytial virus,CHEMBL3638235,Lung,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | TIME = 2.0 hr,,,98
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,IC50,'=',0.9,nM,9.05,,,UO_0000065,20.26,0.39,4.49,14.1,0,CHEMBL4825906,Inhibition of Respiratory syncytial virus A2 fusion protein expressed in HEK293T cells harboring GAL4-NF-kappaB assessed as reduction in cell-cell fusion by luciferase assay,B,BAO_0000219,cell-based format,Human respiratory syncytial virus A2,None,None,HEK293T,None,,,,CHEMBL3856166,Fusion glycoprotein F0,Human respiratory syncytial virus A (strain A2),SINGLE PROTEIN,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,0.9
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',0.5333,hr,,,,UO_0000032,,,,,0,CHEMBL4825899,Half life in human liver microsomes preincubated followed by NADPH addition and measured up to 45 mins by LC-MS/MS analysis,A,BAO_0000251,microsome format,Homo sapiens,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,TIME: <=45,,,32
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CC50,'=',5588,nM,,,,UO_0000065,,,,,0,CHEMBL4825923,Cytotoxicity against human HepG2 cells by MTT assay,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HepG2,None,,,,CHEMBL395,HepG2,Homo sapiens,CELL-LINE,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3307718,,,,5588
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Non-Toxic,,,,,,0,CHEMBL4825960,Genotoxicity in Salmonella typhimurium by Ames test,F,BAO_0000218,organism-based format,Salmonella enterica subsp. enterica serovar Typhimurium,None,None,None,None,,,,CHEMBL351,Salmonella typhimurium,Salmonella enterica subsp. enterica serovar Typhimurium,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Non-Toxic,,,,,,0,CHEMBL4825961,Toxicity in rat by micronucleus test,F,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',55.25,%,,,,UO_0000187,,,,,0,CHEMBL4825963,Antiviral activity against Respiratory syncytial virus A Memphis 37b infected in human assessed as reduction in mean AUC of viral load at 200 mg administered twice daily administered for 5 days by RT-qPCR analysis,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 200.0 mg | TIME = 120.0 hr,,,55.25
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Solubility,'=',417000,nM,,,,UO_0000065,,,,,0,CHEMBL4825907,Thermodynamic solubility in PBS at 1 to 100 uM at pH 7.4 by HPLC-UV method,P,BAO_0000100,small-molecule physicochemical format,None,None,None,None,None,,,,CHEMBL2362975,No relevant target,,NO TARGET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose_Lower = 1.0 microM | Dose_Upper = 100.0 microM,,,417
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Tmax,'=',5.3,hr,,,,UO_0000032,,,,,0,CHEMBL4825934,"Tmax in Sprague-Dawley rat at 50 mg/kg, po measured after 0.02 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,5.3
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',46.4,%,,,,UO_0000187,,,,,0,CHEMBL4825942,Oral bioavailability in CD1 mouse at 10 mg/kg measured after 0.03 to 24 hrs by UHPLC-TOF method,A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,46.4
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Papp,'=',73,10^-6 cm/s,,,,,,,,,0,CHEMBL4825909,Apparent permeability across basolateral side to apical side in MDCK-MDR1 cells at 10 uM measured at 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Canis lupus familiaris,None,None,MDCK-MDR1,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL4295482,Dose = 10.0 microM | TIME = 1.0 hr,,,73
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Ratio,'=',146,,,,,,,,,,0,CHEMBL4825910,Efflux ratio of apparent permeability in MDCK-MDR1 cells at 10 uM measured at 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Canis lupus familiaris,None,None,MDCK-MDR1,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL4295482,Dose = 10.0 microM | TIME = 1.0 hr,,,146
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.82,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 18.02 % | Growth Rate in DMSO (control) = 1.05 None | Replicate number = 2.0 None | Timepoint = 6.0 hours,,,-0.82
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.98,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.95 % | Growth Rate in DMSO (control) = 1.0 None | Replicate number = 2.0 None | Timepoint = 6.0 hours,,,-0.98
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.44,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.82 % | Growth Rate in DMSO (control) = 0.99 None | Replicate number = 2.0 None | Timepoint = 24.0 hours,,,-0.44
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Vdss,'=',22,L.kg-1,,,,UO_0000197,,,,,0,CHEMBL4825914,"Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv administered via gavage measured after 0.02 to 24 hrs by tandem liquid chromatography/mass spectrometry",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 1.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,22
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Vdss,'=',17.6,L.kg-1,,,,UO_0000197,,,,,0,CHEMBL4825970,"Volume of distribution at steady state in Beagle dog at 0.3 mg/kg, iv measured after 0.03 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 0.3 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,17.6
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Vdss,,,,,,Not Determined,,,,,,0,CHEMBL4825973,"Volume of distribution at steady state in Sprague-Dawley rat at 50 mg/kg, po measured after 0.25 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | Time_Lower = 0.25 hrs | Time_Upper = 24.0 hrs,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.81,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 7.06 % | Growth Rate in DMSO (control) = 1.04 None | Replicate number = 1.0 None | Timepoint = 6.0 hours,,,-0.81
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.49,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 20.81 % | Growth Rate in DMSO (control) = 1.1 None | Replicate number = 2.0 None | Timepoint = 0.0 hours,,,0.49
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',3.517,hr,,,,UO_0000032,,,,,0,CHEMBL4825921,Half life in human hepatocytes at 3 uM measured up to 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Homo sapiens,None,None,Hepatocyte,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3308043,Dose = 3.0 microM | TIME: <=60,,,211
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',9.9,hr,,,,UO_0000032,,,,,0,CHEMBL4825929,"Half life in Sprague-Dawley rat at 10 mg/kg, po measured after 0.25 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | Time_Lower = 0.25 hrs | Time_Upper = 24.0 hrs,,,9.9
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Tmax,'=',2,hr,,,,UO_0000032,,,,,0,CHEMBL4825932,"Tmax in CD1 mouse at 10 mg/kg, po measured after 0.083 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | Time_Lower = 0.083 hrs | Time_Upper = 24.0 hrs,,,2
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Cmax,'=',1063.95,nM,,,standard_value was converted from ug.mL-1 to nM using the parent compound MW,UO_0000065,,,,,0,CHEMBL4825939,"Cmax in Sprague-Dawley rat at 50 mg/kg, po measured after 0.02 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | ROUTE: ORAL | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,475
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',132,%,,,,UO_0000187,,,,,0,CHEMBL4825943,Oral bioavailability in Sprague-Dawley rat at 50 mg/kg administered via gavage measured after 0.02 to 24 hrs by tandem liquid chromatography/mass spectrometry,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 50.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,132
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',1.3,nM,8.89,,,UO_0000065,,,,,0,CHEMBL4825945,Antiviral activity against Respiratory syncytial virus A2 infected in human Huh7 cells by Plaque reduction assay,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,Huh-7,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,1.3
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,IC50,'=',1,nM,9,,,UO_0000065,,,,,0,CHEMBL4825947,Antiviral activity against Respiratory syncytial virus B by Plaque reduction assay,F,BAO_0000019,assay format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,1
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Non-Toxic,,,,,,0,CHEMBL4825950,Cytotoxicity against human airway epithelial cells assessed as effect on tight junction at 10 nM preincubated for 2 hrs followed by viral infection and measured after 8 day post infection by H and E staining based assay,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HAE,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 10.0 nM | TIME = 2.0 hr,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,FC,'=',76,,,,,,,,,,0,CHEMBL4825955,Antiviral activity against Respiratory syncytial virus Memphis 37b infected in human HEp2 cells assessed as drug resistance by measuring fold change in EC50 treated over 10 serial passages by plaque assay relative to control,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HEp-2,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,76
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Active,,,,,,0,CHEMBL4825967,Antiviral activity against Respiratory syncytial virus A Memphis 37b infected in human assessed as reduction in AUC of total symptom score at 200 to 350 mg administered twice daily administered for 5 days,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose_Lower = 200.0 mg | Dose_Upper = 350.0 mg | TIME = 120.0 hr,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',630,nM,6.2,,,UO_0000065,,,,,0,CHEMBL3603633,Inhibition of Wnt/beta-catenin transcriptional activity in human HT-29 cells assessed as depletion of beta-catenin level by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,HT-29,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307768,,,,0.63
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,PPB,'=',99.8,%,,,,UO_0000187,,,,,0,CHEMBL3603639,Protein binding in plasma (unknown origin),A,BAO_0000366,cell-free format,Not specified,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,99.8
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,GI,,,,,,Active,,,,,,0,CHEMBL3603668,Cytotoxicity against human H296R cell aggregates grown on matrigel incubated for 5 to 8 days by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,H296R,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Activity,,,,,,Dose-dependent effect,,,,,,0,CHEMBL3603672,Induction of cell cycle arrest in human colon cancer cells assessed as accumulation at G1 phase incubated for 72 hrs by flow cytometry,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Cancer cell lines,None,,,,CHEMBL614375,Cancer cell lines,,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307923,,,,
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (cytolytic),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137726,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (choleostasis),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137727,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (benign tumour),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137735,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (time to onset),,,,,,,,,,,,0,CHEMBL3137739,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (mechanism),,,,,,,,,,,,0,CHEMBL3137740,Proposed mechanism(s) of liver damage. [column 'MEC' in source],T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-0.71,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5060015,Thermal Shift Assay. Domain: start/stop: S229-K512,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHSSGVDLGTENLYFQSMSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGK | Refseq Start/Stop: S229-K512,,,CHEMBL1862,Tyrosine-protein kinase ABL,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-0.71
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.99,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 5.34 % | Growth Rate in DMSO (control) = 1.13 None | Replicate number = 1.0 None | Timepoint = 6.0 hours,,,-0.99
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Vdss,'=',2.91,L.kg-1,,,,UO_0000197,,,,,0,CHEMBL3413813,Volume of distribution at steady state in beagle dog,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL373,Canis familiaris,Canis lupus familiaris,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,2.91
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-2.47,C,,,Thermal Shift Assay,,,,,,0,CHEMBL4650107,Thermal Shift Assay. Domain start/stop: M626-G740,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequence: MHHHHHHSSGVDLGTENLYFQSMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG | Refseq Start/Stop: M626-G740 | Target UniProt Accession: P55201,,,CHEMBL3132741,Peregrin,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-2.47
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.71,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 23.8 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 24.0 hours,,,0.71
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (severe hepatitis),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137728,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.16,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 14.5 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 18.0 hours,,,-0.16
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.62,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 15.79 % | Growth Rate in DMSO (control) = 1.02 None | Replicate number = 2.0 None | Timepoint = 12.0 hours,,,-0.62
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CLH,'=',2.6,uL/min,,,,UO_0000271,,,,,0,CHEMBL4825895,Intrinsic clearance in Beagle dog liver microsomes preincubated followed by NADPH addition and measured up to 45 mins by LC-MS/MS analysis,A,BAO_0000251,microsome format,Canis lupus familiaris,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,TIME: <=45,,,2.6
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Drug uptake,,,,,,Not Active,,,,,,0,CHEMBL3413826,"Drug uptake in lung tissue of Sprague-Dawley rat at 1 mg/kg, iv relative to plasma level",A,BAO_0000218,organism-based format,Rattus norvegicus,CHEMBL3559721,Plasma,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL613643,Lung,Rattus norvegicus,TISSUE,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',51.69,nM,7.29,,,UO_0000065,,,,,0,CHEMBL3603641,Growth inhibition of human A549 cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,A549,None,,,,CHEMBL392,A549,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307651,,,,0.05169
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',23.29,nM,7.63,,,UO_0000065,,,,,0,CHEMBL3603644,Growth inhibition of human SW480 cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,SW480,None,,,,CHEMBL612544,SW480,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307758,,,,0.02329
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603647,Inhibition of STAT3 in human STF3A cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL4026,Signal transducer and activator of transcription 3,Homo sapiens,SINGLE PROTEIN,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL3603657,Inhibition of Wnt/beta-catenin in human STF3A cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',29.92,nM,7.52,,,UO_0000065,,,,,0,CHEMBL3603660,Cytotoxicity against human colon cancer cell aggregates grown on matrigel incubated for 72 hrs by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Cancer cell lines,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307923,,,,0.02992
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',20.01,nM,7.7,,,UO_0000065,,,,,0,CHEMBL3603661,Cytotoxicity against human breast cancer cell aggregates grown on matrigel incubated for 72 hrs by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Cancer cell lines,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307923,,,,0.02001
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,T1/2,'=',35,hr,,,,UO_0000032,,,,,0,CHEMBL3413818,Terminal half life in po dosed human,A,BAO_0000218,organism-based format,Homo sapiens,None,None,None,None,,,,CHEMBL372,Homo sapiens,Homo sapiens,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,35
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (animal toxicity known),,,,,,,,,,,,0,CHEMBL3137736,Animal toxicity known. [column 'TOXIC' in source],T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',8.867,hr,,,,UO_0000032,,,,,0,CHEMBL4825898,Half life in Beagle dog liver microsomes preincubated followed by NADPH addition and measured up to 45 mins by LC-MS/MS analysis,A,BAO_0000251,microsome format,Canis lupus familiaris,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,TIME: <=45,,,532
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,COVC-0672974719,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,IC50,'>',20000,nM,,,No. Measurements = 1,UO_0000065,,,,,0,CHEMBL4651403,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4651402,57,IMI-CARE SARS-CoV-2 Data,,2021,CHEMBL4295411,,,,0.00002
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,Presatovir,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Inhibition,'=',0.45,%,,,,UO_0000187,,,,,0,CHEMBL4513082,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4495565,52,SARS-CoV-2 Screening Data,,2020,CHEMBL4295411,,,,0.45
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CC50,'>',20000,nM,,,,UO_0000065,,,,,0,CHEMBL4825924,Cytotoxicity against human Hep2 cells,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HEp-2,None,,,,CHEMBL614735,HEp-2,Homo sapiens,CELL-LINE,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3307694,,,,20000
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,COVC-3908913129,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,IC50,'>',20000,nM,,,No. Measurements = 1,UO_0000065,,,,,0,CHEMBL4651403,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4651402,57,IMI-CARE SARS-CoV-2 Data,,2021,CHEMBL4295411,,,,0.00002
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Activity,'=',37.44,nM,,,,UO_0000065,,,,,0,CHEMBL4739829,Inhibition of IL1-beta induced MMP3 expression levels in human chondrocytes assessed as MMP3 levels incubated for 2hrs followed by IL1-beta stimulation and measured after 24 hrs by qRT-PCR analysis,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Chondrocyte,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 26.0 hr,,,37.44
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,EC50,'=',6,nM,8.22,,,UO_0000065,16.26,0.3,1.87,7.33,0,CHEMBL4739818,Inhibition of recombinant CLK2 (unknown origin) using Ser/Thr 6 peptide as substrate incubated for 1 hr in presence of ATP by FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 1.0 hr,INHIBITOR,,0.006
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.18,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 9.9 % | Growth Rate in DMSO (control) = 1.19 None | Replicate number = 1.0 None | Timepoint = 0.0 hours,,,-0.18
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.01,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 22.23 % | Growth Rate in DMSO (control) = 1.04 None | Replicate number = 2.0 None | Timepoint = 18.0 hours,,,0.01
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.64,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 3.5 % | Growth Rate in DMSO (control) = 1.0 None | Replicate number = 2.0 None | Timepoint = 18.0 hours,,,-0.64
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Activity,,,,,,Not Active,,,,,,0,CHEMBL3603638,Activity at p-glycoprotein (unknown origin),B,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',20.19,nM,7.7,,,UO_0000065,,,,,0,CHEMBL3603645,Growth inhibition of human HCT116 cells after 72 hrs by APH assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,HCT-116,None,,,,CHEMBL394,HCT-116,Homo sapiens,CELL-LINE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3308372,,,,0.02019
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603650,Inhibition of RAR in human STF cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL2363069,Retinoic acid receptor,Homo sapiens,PROTEIN FAMILY,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL3603653,Inhibition of RXR in human STF3A cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL2363070,Retinoid X receptor,Homo sapiens,PROTEIN FAMILY,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Ratio,'=',10,,,,,,,,,,0,CHEMBL3603659,Ratio of inhibition of NFkappaB in human STF3A cells to inhibition of Wnt/beta-catenin in human STF3A cells,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF3A,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,10
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',38.06,nM,7.42,,,UO_0000065,,,,,0,CHEMBL3603663,Cytotoxicity against human HCT15 cell aggregates grown on matrigel incubated for 72 hrs by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,HCT-15,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307945,,,,0.03806
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Cp,'=',10000,nM,,,,UO_0000065,,,,,0,CHEMBL3603669,"Plasma concentration in mouse at 10 mg/kg, iv",A,BAO_0000218,organism-based format,Mus musculus,CHEMBL3559721,Plasma,None,None,,,,CHEMBL613589,Plasma,Mus musculus,TISSUE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,10000
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Ratio,'=',10,,,,,,,,,,0,CHEMBL3603658,Ratio of inhibition of NFkappaB in human STF cells to inhibition of Wnt/beta-catenin in human STF cells,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,10
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,IC50,'=',20.75,nM,7.68,,,UO_0000065,,,,,0,CHEMBL3603676,Cytotoxicity against human prostate cancer cells after 72 hrs by MTS assay,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Cancer cell lines,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,CHEMBL3307923,,,,0.02075
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,T1/2,'=',4,hr,,,,UO_0000032,,,,,0,CHEMBL3603670,"Terminal half life in mouse plasma at 10 mg/kg, iv",A,BAO_0000218,organism-based format,Mus musculus,CHEMBL3559721,Plasma,None,None,,,,CHEMBL613589,Plasma,Mus musculus,TISSUE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,4
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Cp,'=',1000,nM,,,,UO_0000065,,,,,0,CHEMBL3603671,"Plasma concentration in mouse at 10 mg/kg, iv after 12 hrs",A,BAO_0000218,organism-based format,Mus musculus,CHEMBL3559721,Plasma,None,None,,,,CHEMBL613589,Plasma,Mus musculus,TISSUE,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,1000
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',1.31,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5067447,Thermal Shift Assay. Domain: start/stop: E122-S403,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MKHHHHHHPMSDYDIPTTENLYFQGAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS | Refseq Start/Stop: E122-S403,,,CHEMBL4722,Serine/threonine-protein kinase Aurora-A,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,1.31
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,Presatovir,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Inhibition,'=',-10.15,%,,Outside typical range,,UO_0000187,,,,,0,CHEMBL4808149,Enzymatic assay of human HDAC6 with commercial peptide substrate,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL1865,Histone deacetylase 6,Homo sapiens,SINGLE PROTEIN,CHEMBL4808148,59,Fraunhofer Institute HDAC6 screening,,2021,None,,,,-10.15
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.44,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 5.63 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 24.0 hours,,,-0.44
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.57,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 3.38 % | Growth Rate in DMSO (control) = 1.0 None | Replicate number = 2.0 None | Timepoint = 24.0 hours,,,-0.57
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-0.16,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5066518,Thermal Shift Assay. Domain: start/stop: M1-S360,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHSSGVDLGTENLYFQSMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS | Refseq Start/Stop: M1-S360,,,CHEMBL4040,MAP kinase ERK2,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-0.16
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL3603656,Inhibition of Wnt/beta-catenin in human STF cells at 1 uM after 24 hrs by TCF luciferase promoter reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.43,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 29.19 % | Growth Rate in DMSO (control) = 1.04 None | Replicate number = 1.0 None | Timepoint = 24.0 hours,,,0.43
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.02,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 22.03 % | Growth Rate in DMSO (control) = 1.02 None | Replicate number = 2.0 None | Timepoint = 24.0 hours,,,-0.02
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Fu,'=',0.52,,,,,,,,,,0,CHEMBL4825891,Protein binding in rat plasma assessed as unbound fraction at 5 uM by LC-MS/MS analysis based equilibrium dialysis method,A,BAO_0000366,cell-free format,Rattus norvegicus,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 5.0 microM,,,52
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,IC50,'=',1.4,nM,8.85,,,UO_0000065,,,,,0,CHEMBL4825946,Antiviral activity against Respiratory syncytial virus A by Plaque reduction assay,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,1.4
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,log(activity),'=',2.35,,,,,,,,,,0,CHEMBL4825949,Antiviral activity against Respiratory syncytial virus infected in human airway epithelial cells assessed as reduction in RSV titer at 10 nM preincubated for 2 hrs followed by viral infection and measured after 8 day post infection by luminescence assay relative to control,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HAE,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 10.0 nM | TIME = 2.0 hr,,,2.35
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Non-Toxic,,,,,,0,CHEMBL4825951,Cytotoxicity against human airway epithelial cells assessed as change in cell morphology at 10 nM preincubated for 2 hrs followed by viral infection and measured after 8 day post infection by H and E staining based assay,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HAE,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose = 10.0 nM | TIME = 2.0 hr,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',1.8,hr,,,,UO_0000032,,,,,0,CHEMBL4825925,"Half life in Sprague-Dawley rat at 1 mg/kg, iv measured after 0.02 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 1.0 mg.kg-1 | Time_Lower = 0.02 hrs | Time_Upper = 24.0 hrs,,,1.8
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',4.2,hr,,,,UO_0000032,,,,,0,CHEMBL4825926,"Half life in CD1 mouse at 1 mg/kg, iv measured after 0.03 to 24 hrs by UHPLC-TOF method",A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 1.0 mg.kg-1 | Time_Lower = 0.03 hrs | Time_Upper = 24.0 hrs,,,4.2
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,PRESATOVIR,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Inhibition,'=',22.59,%,,,,UO_0000187,,,,,0,CHEMBL4303805,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging,F,BAO_0000218,organism-based format,Homo sapiens,None,None,Caco-2,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4303101,52,SARS-CoV-2 Screening Data,,2020,CHEMBL3307519,,,,22.59
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Ratio IC50,'=',13.35,,,,,,,,,,0,CHEMBL5251377,Selectivity ratio of IC50 for recombinant human GSK-3beta expressed in Sf9 insect cells to IC50 for recombinant human DYRK1A expressed in Sf9 insect cells,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,,,,13.35
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',88.98,nM,7.05,,,UO_0000065,,,,,0,CHEMBL4825953,Antiviral activity against Respiratory syncytial virus Memphis 37b infected in human HEp2 cells treated over 10 serial passages by plaque assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HEp-2,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,88.98
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,CLH,'=',6.58,uL/min,,,,UO_0000271,,,,,0,CHEMBL4825918,Intrinsic clearance in human hepatocytes at 3 uM assessed per million cells measured up to 60 mins by LC-MS/MS analysis,A,BAO_0000219,cell-based format,Homo sapiens,None,None,Hepatocyte,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,CHEMBL3308043,Dose = 3.0 microM | TIME: <=60,,,6.58
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (association with vascular disease),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137732,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (steatosis),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137733,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (malignant tumour),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137734,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",T,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,Presatovir,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Inhibition,'=',0.45,%,,,,UO_0000187,,,,,0,CHEMBL4513082,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4495565,52,SARS-CoV-2 Screening Data,,2020,CHEMBL4295411,,,,0.45
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Drug uptake,,,,,,Active,,,,,,0,CHEMBL3413828,Drug uptake in bovine lung relative to plasma level,A,BAO_0000366,cell-free format,Bos taurus,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,FC,'=',4.23,,,,,,,,,,0,CHEMBL3411999,"Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as log10 reduction in viral load at 50 mg, po as loading dose followed by 25 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post infection measured after 84 hrs after first dose relative to placebo",F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,4.23
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.73,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 29.86 % | Growth Rate in DMSO (control) = 1.02 None | Replicate number = 1.0 None | Timepoint = 18.0 hours,,,0.73
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Kd,'=',155.07,nM,6.81,,,UO_0000065,13.47,0.24,0.46,6.07,0,CHEMBL5251385,Binding affinity to human GSK-3beta assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL262,Glycogen synthase kinase-3 beta,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME <= 4.0 hr,INHIBITOR,,155.07
CHEMBL3601411,TEGAVIVINT,2,588.75,1,3.79,"14, BC-2059",C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1,Activity,,,,,,Active,,,,,,0,CHEMBL3603675,Inhibition of Wnt/beta-catenin in human STF cells assessed as effect on Wnt-3a-CM-induced TopFlash activity incubated for 12 hrs with Wnt-3a-conditioned medium followed by 1 uM compound dosing,B,BAO_0000219,cell-based format,Homo sapiens,None,None,STF,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3600343,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,'=',92,%,,,,UO_0000187,,,,,0,CHEMBL4825956,"Antiviral activity against Respiratory syncytial virus A2 infected in Balb/C mouse assessed as reduction in viral titers in lung homogenates at 10 mg/kg, po treated 2 hrs prior to viral infection followed by compound redosing at 24 hrs and measured after 5 days post infection by plaque assay relative to control",F,BAO_0000218,organism-based format,Human respiratory syncytial virus,CHEMBL3638235,Lung,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,DOSE = 10.0 mg.kg-1 | TIME = 2.0 hr,,,92
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Toxic,,,,,,0,CHEMBL4825959,Cardiotoxicity in dog assessed as effect on QT interval by telemetry,T,BAO_0000019,assay format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,,,,
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (chronic liver disease),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137729,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (granulomatous hepatitis),'=',0,,,,references out of a total of 1,,,,,,0,CHEMBL3137731,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.43,nM,9.37,,,UO_0000065,,,,,0,CHEMBL3413822,Antiviral activity against Respiratory syncytial virus type B,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,0.43
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Drug metabolism,'=',28,%,,,,UO_0000187,,,,,0,CHEMBL4620880,Metabolic stability in dog liver microsomes assessed as compound metabolized after 15 mins,A,BAO_0000251,microsome format,Canis lupus familiaris,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,28
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,T1/2,'=',10,hr,,,,UO_0000032,,,,,0,CHEMBL3413817,Terminal half life in po dosed cynomolgus monkey,A,BAO_0000218,organism-based format,Macaca fascicularis,None,None,None,None,,,,CHEMBL613847,Cynomolgus monkey,Macaca fascicularis,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,10
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL5237381,Inhibition of human CLK2 mediated phosphorylation of SRSF4 in hMSCs assessed by TCF/LEF reporter assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.58,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.92 % | Growth Rate in DMSO (control) = 0.99 None | Replicate number = 2.0 None | Timepoint = 18.0 hours,,,-0.58
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.42,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 14.77 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 2.0 None | Timepoint = 24.0 hours,,,-0.42
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (moderate),'=',3.6,%,,,,UO_0000187,,,,,0,CHEMBL3137723,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,3.6
CHEMBL1201586,PALIVIZUMAB,4,None,None,None,PALIVIZUMAB,,Hepatotoxicity (acute),'=',0,%,,,,UO_0000187,,,,,0,CHEMBL3137725,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",T,BAO_0000221,tissue-based format,Homo sapiens,CHEMBL3559723,Liver,None,None,,,,CHEMBL3879801,NON-PROTEIN TARGET,,NON-MOLECULAR,CHEMBL3137667,1,Scientific Literature,Gastroenterol Clin Biol,2004,None,,,,0
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Ratio IC50,'=',5.99,,,,,,,,,,0,CHEMBL5251381,Selectivity ratio of IC50 for recombinant human CLK1 expressed in Sf9 insect cells to IC50 for recombinant human DYRK1A expressed in Escherichia coli,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,,,,5.99
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,TIME,'=',1.5,hr,,,,UO_0000032,,,,,0,CHEMBL5251387,Binding affinity to human CLK1 assessed as residence time measured upto 240 min by TR-FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4224,Dual specificity protein kinase CLK1,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME <= 4.0 hr,INHIBITOR,,89.97
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',7.8,nM,8.11,,,UO_0000065,16.04,0.29,1.76,7.22,1,CHEMBL5105878,Inhibition of CLK2 (unknown origin),B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5104139,1,Scientific Literature,Bioorg Med Chem,2022,None,,INHIBITOR,,7.8
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.33,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 16.22 % | Growth Rate in DMSO (control) = 100.0 None | Replicate number = 1.0 None | Timepoint = 0.0 hours,,,-0.33
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.13,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 17.8 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 2.0 None | Timepoint = 24.0 hours,,,-0.13
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,46b; JNJ 53718678,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.46,nM,9.34,,,UO_0000065,,,,,0,CHEMBL5147989,Antiviral activity against recombinant rgRSV224 infected in human HeLa cells assessed as inhibition of viral replication at MOI of 0.02 measured after 3 days by laser microscopy,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HeLa,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL5143686,1,Scientific Literature,J Med Chem,2022,None,TIME = 72.0 hr,,,0.46
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.95,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 3.54 % | Growth Rate in DMSO (control) = 1.05 None | Replicate number = 2.0 None | Timepoint = 6.0 hours,,,-0.95
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.81,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 3.37 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 2.0 None | Timepoint = 12.0 hours,,,-0.81
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Ratio,'=',26,,,,,,,,,,0,CHEMBL3413824,"Ratio of AUC (0 to 12 hrs) in lung to AUC (0 to 12 hrs) in plasma of Sprague-Dawley rat at 1 mg/kg, iv",A,BAO_0000218,organism-based format,Rattus norvegicus,CHEMBL3559721,Plasma,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,26
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,F,'=',60,%,,,,UO_0000187,,,,,0,CHEMBL3413820,Oral bioavailability in cynomolgus monkey at 4 mg/kg,A,BAO_0000218,organism-based format,Macaca fascicularis,None,None,None,None,,,,CHEMBL613847,Cynomolgus monkey,Macaca fascicularis,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,60
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.71,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 13.14 % | Growth Rate in DMSO (control) = 1.04 None | Replicate number = 1.0 None | Timepoint = 12.0 hours,,,-0.71
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',9.09,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5065589,Thermal Shift Assay. Domain: start/stop: M26-R383,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARAHHHHHH | Refseq Start/Stop: M26-R383,,,CHEMBL262,Glycogen synthase kinase-3 beta,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,9.09
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,COVC-0672974719,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,IC50,'>',19952.62,nM,,,No. Measurements = 1,UO_0000065,,,,,0,CHEMBL4651403,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4651402,57,IMI-CARE SARS-CoV-2 Data,,2021,CHEMBL4295411,,,,4.7
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Drug uptake,,,,,,Active,,,,,,0,CHEMBL3413829,Drug uptake in dog lung relative to plasma level,A,BAO_0000366,cell-free format,Canis lupus familiaris,CHEMBL3559721,Plasma,None,None,,,,CHEMBL613431,Plasma,Canis lupus familiaris,TISSUE,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Ratio IC50,'=',1.85,,,,,,,,,,0,CHEMBL5251376,Selectivity ratio of IC50 for recombinant human DYRK1B expressed in Sf9 insect cells to IC50 for recombinant human DYRK1A expressed in Sf9 insect cells,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,,,,1.85
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.82,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 13.18 % | Growth Rate in DMSO (control) = 1.12 None | Replicate number = 1.0 None | Timepoint = 6.0 hours,,,-0.82
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,COVC-3908913129,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,IC50,'>',19952.62,nM,,,No. Measurements = 1,UO_0000065,,,,,0,CHEMBL4651403,Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging,F,BAO_0000218,organism-based format,Chlorocebus sabaeus,None,None,Vero C1008,None,,,,CHEMBL4303835,SARS-CoV-2,Severe acute respiratory syndrome coronavirus 2,ORGANISM,CHEMBL4651402,57,IMI-CARE SARS-CoV-2 Data,,2021,CHEMBL4295411,,,,4.7
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,CL,'=',6,mL.min-1.kg-1,,,,,,,,,0,CHEMBL3413811,"Clearance in cynomolgus monkey at 1 mg/kg, iv administered as infusion over 30 mins",A,BAO_0000218,organism-based format,Macaca fascicularis,None,None,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL613847,Cynomolgus monkey,Macaca fascicularis,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,0.36
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.1,nM,10,,,UO_0000065,,,,,0,CHEMBL3413823,Antiviral activity against Respiratory syncytial virus clinical isolates,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,0.1
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,CC50,'>',20000,nM,,,,UO_0000065,,,,,0,CHEMBL3413805,Cytotoxicity against human Hep2 cells after 4 days by cell-Titer Glo assay,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HEp-2,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,CHEMBL3307694,,,,20
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.78,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.93 % | Growth Rate in DMSO (control) = 1.02 None | Replicate number = 2.0 None | Timepoint = 12.0 hours,,,-0.78
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.25,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 19.78 % | Growth Rate in DMSO (control) = 33.68 None | Replicate number = 2.0 None | Timepoint = 0.0 hours,,,-0.25
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,EC50,'=',5,nM,8.3,,,UO_0000065,16.42,0.3,1.95,7.4,0,CHEMBL4739817,Inhibition of recombinant DYRK1A (unknown origin) using Ser/Thr 18 peptide as substrate incubated for 1 hr in presence of ATP by FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 1.0 hr,INHIBITOR,,0.005
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.075,ug.mL-1,,,,UO_0000274,,,,,0,CHEMBL4620887,Antiviral activity against RSV Long infected in po dosed cotton rat model assessed as reduction in viral titer in broncho alveolar lavage fluid pretreated for 1 hr followed by viral infection measured after 4 days by plaque reduction assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,75
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Drug metabolism,'=',60,%,,,,UO_0000187,,,,,0,CHEMBL4620879,Metabolic stability in rat liver microsomes assessed as compound metabolized after 15 mins,A,BAO_0000251,microsome format,Rattus norvegicus,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,60
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,CL,'=',65,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4620881,"Clearance in Sprague-Dawley rat plasma at 2.5 mg/kg, iv",A,BAO_0000218,organism-based format,Rattus norvegicus,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,3.9
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,1; JNJ-53718678,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Inhibition,,,%,,,Not Active,UO_0000187,,,,,0,CHEMBL4822352,Antiviral activity against RSV infected in human A549 cells assessed as reduction in viral titer at 10 uM measured after 15 hrs by immunostaining analysis,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,A549,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4819107,1,Scientific Literature,Bioorg Med Chem,2021,None,Dose = 10.0 microM | TIME = 15.0 hr,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,EC50,'=',30,nM,7.52,,,UO_0000065,,,,,0,CHEMBL4739827,Induction of chondrogenesis in human MSC assessed as incubated for 6 days by rhodamine B and Nile red staining based imaging analysis,F,BAO_0000221,tissue-based format,Homo sapiens,None,None,BMMSC,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 144.0 hr,,,30
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Activity,'=',44.97,nM,,,,UO_0000065,,,,,0,CHEMBL4739830,Inhibition of IL1-beta induced MMP-13 expression levels in human chondrocytes assessed as MMP-13 levels incubated for 2hrs followed by IL1-beta stimulation and measured after 24 hrs by qRT-PCR analysis,F,BAO_0000219,cell-based format,Homo sapiens,None,None,Chondrocyte,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 26.0 hr,,,44.97
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,F,'=',46,%,,,,UO_0000187,,,,,0,CHEMBL3413807,Oral bioavailability in Sprague-Dawley rat at 4 mg/kg,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL376,Rattus norvegicus,Rattus norvegicus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,46
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,"6-2; JNJ 53718678, JNJ-678",CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.2,nM,9.7,,,UO_0000065,,,,,0,CHEMBL4376911,Antiviral activity against RSV B infected in HeLa cells,F,BAO_0000219,cell-based format,Human respiratory syncytial virus B,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.2
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.06,,,,,,,,,,0,CHEMBL4725213,Incucyte cell viability with human fibroblast,T,BAO_0000219,cell-based format,Homo sapiens,None,None,Fibroblast,None,,,,CHEMBL5314315,Fibroblast,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL4295351,Compound concentration = 10.0 uM | Confluency (%) = 22.04 % | Growth Rate in DMSO (control) = 1.2 None | Replicate number = 2.0 None | Timepoint = 6.0 hours,,,-0.06
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.89,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.03 % | Growth Rate in DMSO (control) = 1.03 None | Replicate number = 1.0 None | Timepoint = 12.0 hours,,,-0.89
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',6049,nM,5.22,,,UO_0000065,10.32,0.19,-1.13,4.65,0,CHEMBL5251371,Inhibition of recombinant human DYRK2 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4376,Dual-specificity tyrosine-phosphorylation regulated kinase 2,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,6.049
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.37,nM,9.43,,,UO_0000065,,,,,0,CHEMBL3413799,Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathogenicity after 4 days by cell-Titer Glo assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,HEp-2,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,CHEMBL3307694,,,,0.37
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,Drug uptake,,,,,,Not Active,,,,,,0,CHEMBL3413827,"Drug uptake in epithelial lining fluid of Sprague-Dawley rat at 1 mg/kg, iv relative to plasma level",A,BAO_0000218,organism-based format,Rattus norvegicus,CHEMBL3559721,Plasma,None,None,DOSE = 1.0 mg.kg-1 | ROUTE: Intravenous,,,CHEMBL613652,Plasma,Rattus norvegicus,TISSUE,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,FC,'=',1.8,,,,,,,,,,0,CHEMBL3411893,"Antiviral activity against Respiratory syncytial virus infected in cotton rat assessed as log10 reduction in plaque forming unit equivalent in lung tissue at 0.3 to 30 mg/kg, ip administered 1 hr prior infection measured on day 4 by RT-qPCR analysis relative to placebo",F,BAO_0000218,organism-based format,Respiratory syncytial virus,CHEMBL3638235,Lung,None,None,DOSE: 0.3-30 | ROUTE: Intraperitoneal,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,1.8
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-2.55,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5060944,Thermal Shift Assay. Domain: start/stop: N44-E168,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHSSGVDLGTENLYFQSMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE | Refseq Start/Stop: N44-E168 | Target UniProt Accession: O60885,,,CHEMBL1163125,Bromodomain-containing protein 4,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-2.55
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,Activity,,,,,,Non-Toxic,,,,,,0,CHEMBL4825962,Induction of toxicity in human at 175 to 350 mg,A,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,Dose_Lower = 175.0 mg | Dose_Upper = 350.0 mg,,,
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,20; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,T1/2,'=',1.333,hr,,,,UO_0000032,,,,,0,CHEMBL4825897,Half life in Sprague-Dawley rat liver microsomes preincubated followed by NADPH addition and measured up to 45 mins by LC-MS/MS analysis,A,BAO_0000251,microsome format,Rattus norvegicus,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4825662,1,Scientific Literature,J Med Chem,2021,None,TIME: <=45,,,80
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,permeability,'=',19,10'-6 cm/s,,,,,,,,,0,CHEMBL3413802,Permeability from basolateral to apical side of human Caco2 cells at 10 uM by LC/MS/MS analysis,A,BAO_0000219,cell-based format,Homo sapiens,None,None,Caco-2,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,CHEMBL3307519,,,,19
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.32,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 24.11 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 2.0 None | Timepoint = 12.0 hours,,,0.32
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.98,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 13.35 % | Growth Rate in DMSO (control) = 1.21 None | Replicate number = 1.0 None | Timepoint = 6.0 hours,,,-0.98
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.56,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 12.69 % | Growth Rate in DMSO (control) = 1.03 None | Replicate number = 1.0 None | Timepoint = 12.0 hours,,,-0.56
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,"3, GS-5806",Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.43,nM,9.37,,,UO_0000065,,,,,0,CHEMBL3413821,Antiviral activity against Respiratory syncytial virus type A,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL3407466,1,Scientific Literature,J Med Chem,2015,None,,,,0.43
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1; SM04690,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',8,nM,8.1,,,UO_0000065,16.02,0.29,1.75,7.21,0,CHEMBL5150994,Inhibition of human CLK2,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5149981,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,8
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.5012,nM,9.3,,,UO_0000065,18.57,0.38,5.45,11.79,0,CHEMBL4620868,Inhibition of GFP-fused RSV 224 fusion protein infected in human HeLa cells assessed as reduction in viral replication after 3 days by laser microscopic analysis,B,BAO_0000219,cell-based format,Respiratory syncytial virus,None,None,HeLa,None,,,,CHEMBL2364165,Fusion glycoprotein F0,Human respiratory syncytial virus,SINGLE PROTEIN,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,CHEMBL3308376,,,,9.3
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',582.6,nM,6.24,,,UO_0000065,12.33,0.22,-0.12,5.55,0,CHEMBL5251365,Inhibition of recombinant human CLK1 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4224,Dual specificity protein kinase CLK1,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.5826
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Fu,'=',0.06,,,,,,,,,,0,CHEMBL4620886,Protein binding in human plasma assessed as unbound fraction,A,BAO_0000366,cell-free format,Homo sapiens,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,6
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,SM04690,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',26.9,nM,7.57,,,UO_0000065,14.97,0.27,1.22,6.74,1,CHEMBL5105892,Inhibition of DYRK1A (unknown origin),B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5104139,1,Scientific Literature,Bioorg Med Chem,2022,None,,INHIBITOR,,26.9
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.48,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 6.4 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 1.0 None | Timepoint = 18.0 hours,,,-0.48
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',26.9,nM,7.57,,,UO_0000065,14.97,0.27,1.22,6.74,0,CHEMBL5237383,Inhibition of human DYRK1A,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,26.9
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.42,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 30.78 % | Growth Rate in DMSO (control) = 12.28 None | Replicate number = 2.0 None | Timepoint = 0.0 hours,,,-0.42
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Delta TM,'=',-0.4,C,,,Thermal Shift Assay,,,,,,0,CHEMBL5068376,Thermal Shift Assay. Domain: start/stop: G861-E979,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,Protein Sequences: MHHHHHHHHHHSSGVDLGTENLYFQSMGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYPEKRFPKPE | Refseq Start/Stop: G861-E979 | Target UniProt Accession: O15164,,,CHEMBL3108638,Transcription intermediary factor 1-alpha,Homo sapiens,SINGLE PROTEIN,CHEMBL4632348,55,EUbOPEN Chemogenomic Library,,,None,Compound concentration = 20.0 uM | Protein concentration = 2.0 uM | Result type: QC Liability,,,-0.4
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,CC50,'>',50000,nM,,,,UO_0000065,,,,,0,CHEMBL4620869,Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by ATPlite assay,A,BAO_0000219,cell-based format,Homo sapiens,None,None,HeLa,None,,,,CHEMBL399,HeLa,Homo sapiens,CELL-LINE,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,CHEMBL3308376,,,,50
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',13.6,nM,7.87,,,UO_0000065,15.56,0.28,1.52,7.01,0,CHEMBL5251366,Inhibition of recombinant human CLK2 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.0136
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'>',10000,nM,,,,UO_0000065,,,,,0,CHEMBL5251372,Inhibition of recombinant human DYRK3 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4575,Dual-specificity tyrosine-phosphorylation regulated kinase 3,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,,,10
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',2100,nM,5.68,,,UO_0000065,,,,,0,CHEMBL5251390,Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay,T,BAO_0000219,cell-based format,Mus musculus,None,None,HT-22,None,,,,CHEMBL614316,HT-22,Mus musculus,CELL-LINE,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,CHEMBL3307590,TIME = 48.0 hr,,,2.1
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',41.1,nM,7.39,,,UO_0000065,14.61,0.27,1.04,6.58,0,CHEMBL5251379,Inhibition of recombinant human DYRK1A expressed in Escherichia coli using DYRKtide peptide as substrate incubated for 110 mins in presence of ATP by non-radioactive ADP-Glo luminescence microplate reader assay,B,BAO_0000019,assay format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.833 hr,INHIBITOR,,0.0411
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,"6-2; JNJ 53718678, JNJ-678",CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,CL,'=',9,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4376912,"Plasma clearance in Beagle dog at 2 mg/ml, iv or 1.2 mg/ml, po measured up to 24 hrs by LC-MS/MS analysis",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,9
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,7-2; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',63,%,,,,UO_0000187,,,,,0,CHEMBL4376920,Oral bioavailability in dog,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,63
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',0.98,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 37.32 % | Growth Rate in DMSO (control) = 1.01 None | Replicate number = 2.0 None | Timepoint = 18.0 hours,,,0.98
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,7-2; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',46,%,,,,UO_0000187,,,,,0,CHEMBL4376918,Oral bioavailability in mouse,A,BAO_0000218,organism-based format,Mus musculus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,46
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,7-2; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,F,'=',42,%,,,,UO_0000187,,,,,0,CHEMBL4376919,Oral bioavailability in rat,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,42
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,12-3; GS-5806,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.43,nM,9.37,,,UO_0000065,,,,,0,CHEMBL4376925,Antiviral activity against RSV type A infected in Hep2 cells for 3 days by TMB-ELISA method,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.43
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,1; GS-5806,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',1193,nM,5.92,,,UO_0000065,11.13,0.22,2.95,4.7,0,CHEMBL4618859,Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 hrs followed by replacement of fresh medium containing compounds and measured after 3 days by ELISA,B,BAO_0000219,cell-based format,Human respiratory syncytial virus,None,None,HEp-2,None,,P03420,D486N,CHEMBL3856166,Fusion glycoprotein F0,Human respiratory syncytial virus A (strain A2),SINGLE PROTEIN,CHEMBL4616695,1,Scientific Literature,ACS Med Chem Lett,2020,CHEMBL3307694,,,,1193
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,EUB0001024a,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.47,,,,,,,,,,0,CHEMBL4725214,Incucyte cell viability with U2OS,T,BAO_0000219,cell-based format,Homo sapiens,None,None,U2OS,None,,,,CHEMBL615023,U2OS,Homo sapiens,CELL-LINE,CHEMBL5303304,55,EUbOPEN Chemogenomic Library,,2023,CHEMBL3307757,Compound concentration = 10.0 uM | Confluency (%) = 15.4 % | Growth Rate in DMSO (control) = 1.0 None | Replicate number = 2.0 None | Timepoint = 18.0 hours,,,-0.47
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',48,nM,7.32,,,UO_0000065,14.48,0.26,0.97,6.52,0,CHEMBL5251369,Inhibition of recombinant human DYRK1A expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.048
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,123,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,EC50,'=',56,nM,7.25,,,UO_0000065,14.34,0.26,0.9,6.46,0,CHEMBL4739819,Inhibition of recombinant CLK3 (unknown origin) using Ser/Thr 18 peptide as substrate incubated for 1 hr in presence of ATP by FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4226,Dual specificity protein kinase CLK3,Homo sapiens,SINGLE PROTEIN,CHEMBL4739717,38,SureChEMBL Patent Bioactivity Data,,2020,None,TIME = 1.0 hr,INHIBITOR,,0.056
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,7-2; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',0.1,nM,10,,,UO_0000065,,,,,0,CHEMBL4376917,Antiviral activity against Respiratory syncytial virus B plaque reduction assay,F,BAO_0000019,assay format,Human respiratory syncytial virus B,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.1
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Ratio AUC,'=',3.5,,,,,,,,,,0,CHEMBL4620882,"Ratio of AUC (0 to last) in lung to plasma of Sprague-Dawley rat at 2.5 mg/kg, iv or 10 mg/kg, po",A,BAO_0000218,organism-based format,Rattus norvegicus,CHEMBL3987302,Lung/Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,3.5
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',7.8,nM,8.11,,,UO_0000065,16.04,0.29,1.76,7.22,0,CHEMBL5237382,Inhibition of human CLK2,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,7.8
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Kd,'=',5.889,nM,8.23,,,UO_0000065,16.28,0.3,1.88,7.33,0,CHEMBL5251384,Binding affinity to human CLK1 assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4224,Dual specificity protein kinase CLK1,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME <= 4.0 hr,INHIBITOR,,5.889
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Activity,,,,,,Dose-dependent effect,,,,,,0,CHEMBL4620888,Antiviral activity against RSV Long infected in po dosed cotton rat model assessed as reduction in viral titer in lung lavage fluid pretreated for 1 hr followed by viral infection measured after 4 days by plaque reduction assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,1; GS-5806,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.1,nM,10,,,UO_0000065,18.79,0.38,7.03,7.94,0,CHEMBL4618858,Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by Celltiter-Glo viability assay,B,BAO_0000219,cell-based format,Human respiratory syncytial virus A2,None,None,HEp-2,None,,,,CHEMBL2364165,Fusion glycoprotein F0,Human respiratory syncytial virus,SINGLE PROTEIN,CHEMBL4616695,1,Scientific Literature,ACS Med Chem Lett,2020,CHEMBL3307694,,,,0.1
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Activity,,,,,,Dose-dependent effect,,,,,,0,CHEMBL4620887,Antiviral activity against RSV Long infected in po dosed cotton rat model assessed as reduction in viral titer in broncho alveolar lavage fluid pretreated for 1 hr followed by viral infection measured after 4 days by plaque reduction assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,
CHEMBL3410450,PRESATOVIR,2,532.07,1,2.97,12-3; GS-5806,Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,EC50,'=',0.43,nM,9.37,,,UO_0000065,,,,,0,CHEMBL4376924,Antiviral activity against RSV type B infected in Hep2 cells for 3 days by TMB-ELISA method,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.43
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,"6-2; JNJ 53718678, JNJ-678",CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.46,nM,9.34,,,UO_0000065,,,,,0,CHEMBL4376909,Antiviral activity against recombinant RSV infected in HeLa cells assessed as reduction in eGFP expression after 3 days by laser microscopic analysis,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.46
CHEMBL4297497,SISUNATOVIR,2,446.45,0,4.56,7-2; RV521,NCc1ccc2c(c1)nc(CN1C(=O)C3(CC3)c3ccc(F)cc31)n2CCCC(F)(F)F,EC50,'=',0.1,nM,10,,,UO_0000065,,,,,0,CHEMBL4376916,Antiviral activity against Respiratory syncytial virus A plaque reduction assay,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.1
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,"6-2; JNJ 53718678, JNJ-678",CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.2,nM,9.7,,,UO_0000065,,,,,0,CHEMBL4376910,Antiviral activity against RSV A infected in HeLa cells,F,BAO_0000218,organism-based format,Human respiratory syncytial virus,None,None,None,None,,,,CHEMBL613127,Human orthopneumovirus,Human orthopneumovirus,ORGANISM,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,0.2
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Drug metabolism,'=',1,%,,,,UO_0000187,,,,,0,CHEMBL4620871,Metabolic stability in human liver microsomes assessed as compound metabolized after 15 mins,A,BAO_0000251,microsome format,Homo sapiens,CHEMBL3559723,Liver,None,Microsome,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,1
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1; SM04690,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,TIME,'=',0.5288,hr,,,,UO_0000032,,,,,0,CHEMBL5251386,Binding affinity to human DYRK1A assessed as residence time measured upto 240 min by TR-FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME <= 4.0 hr,INHIBITOR,,31.73
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1; SM04690,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,TIME,'=',0.0425,hr,,,,UO_0000032,,,,,0,CHEMBL5251388,Binding affinity to human GSK-3beta assessed as residence time measured upto 240 min by TR-FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL262,Glycogen synthase kinase-3 beta,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME <= 4.0 hr,INHIBITOR,,2.55
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL5237378,Inhibition of Human CLK2 mediated phosphorylation of SRSF4 in human chondrocytes assessed by TCF/LEF reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',89,nM,7.05,,,UO_0000065,13.95,0.25,0.7,6.28,0,CHEMBL5251370,Inhibition of recombinant human DYRK1B expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL5543,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.089
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',97.2,nM,7.01,,,UO_0000065,13.87,0.25,0.66,6.25,0,CHEMBL5251380,Inhibition of recombinant human DYRK1B expressed in Sf9 insect cells using DYRKtide peptide as substrate incubated for 110 mins in presence of ATP by non-radioactive ADP-Glo luminescence microplate reader assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL5543,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.833 hr,INHIBITOR,,0.0972
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,"6-2; JNJ 53718678, JNJ-678",CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,T1/2,'=',4.1,hr,,,,UO_0000032,,,,,0,CHEMBL4376913,"Half life in Beagle dog at 2 mg/ml, iv or 1.2 mg/ml, po measured up to 24 hrs by LC-MS/MS analysis",A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,4.1
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,F,'=',42,%,,,,UO_0000187,,,,,0,CHEMBL4620883,Oral bioavailability in Sprague-Dawley rat at 10 mg/kg,A,BAO_0000218,organism-based format,Rattus norvegicus,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,42
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,EC50,'=',0.081,ug.mL-1,,,,UO_0000274,,,,,0,CHEMBL4620888,Antiviral activity against RSV Long infected in po dosed cotton rat model assessed as reduction in viral titer in lung lavage fluid pretreated for 1 hr followed by viral infection measured after 4 days by plaque reduction assay,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,None,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,81
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL5237376,Inhibition of Human CLK2 mediated phosphorylation of SRSF6 in human chondrocytes assessed by TCF/LEF reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,F,'=',89,%,,,,UO_0000187,,,,,0,CHEMBL4620885,Oral bioavailability in dog at 5 mg/kg,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,89
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,"6-2; JNJ 53718678, JNJ-678",CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,F,'=',89,%,,,,UO_0000187,,,,,0,CHEMBL4376914,Oral bioavailability in Beagle dog at 1.2 mg/ml measured up to 24 hrs by LC-MS/MS analysis,A,BAO_0000218,organism-based format,Canis lupus familiaris,None,None,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4376802,1,Scientific Literature,J Med Chem,2019,None,,,,89
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',246.2,nM,6.61,,,UO_0000065,13.07,0.24,0.26,5.89,0,CHEMBL5251378,Inhibition of recombinant human CLK1 expressed in Sf9 insect cells using myelin basic protein as substrate incubated for 110 mins in presence of ATP by non-radioactive ADP-Glo luminescence microplate reader assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4224,Dual specificity protein kinase CLK1,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.833 hr,INHIBITOR,,0.2462
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL5237380,Inhibition of human CLK2 mediated phosphorylation of SRSF5 in hMSCs assessed by TCF/LEF reporter assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,1; JNJ-53718678,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL4822340,Antiviral activity against RSV infected in human A549 cells assessed as reduction in viral RNA at 10 uM measured upto 24 hrs by qRT-PCR analysis,F,BAO_0000218,organism-based format,Respiratory syncytial virus,None,None,A549,None,,,,CHEMBL612679,Respiratory syncytial virus,Respiratory syncytial virus,ORGANISM,CHEMBL4819107,1,Scientific Literature,Bioorg Med Chem,2021,None,Dose = 10.0 microM | TIME: <=24,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Kd,'=',19.95,nM,7.7,,,UO_0000065,15.23,0.28,1.35,6.86,0,CHEMBL5251383,Binding affinity to human DYRK1A assessed as equilibrium dissociation constant measured upto 240 min by TR-FRET assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME <= 4.0 hr,INHIBITOR,,19.953
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'>',10000,nM,,,,UO_0000065,,,,,0,CHEMBL5251363,Inhibition of recombinant human CDK5/p25 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL1907600,Cyclin-dependent kinase 5/CDK5 activator 1,Homo sapiens,PROTEIN COMPLEX,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,,,10
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Growth Rate,'=',-0.55,,,,,,,,,,0,CHEMBL4725212,Incucyte cell viability with HEK293T,T,BAO_0000219,cell-based format,Homo sapiens,None,None,HEK-293T,None,,,,CHEMBL3706568,HEK-293T,Homo sapiens,CELL-LINE,CHEMBL5058564,55,EUbOPEN Chemogenomic Library,,2022,CHEMBL3706569,Compound concentration = 10.0 uM | Confluency (%) = 7.28 % | Growth Rate in DMSO (control) = 1.02 None | Replicate number = 1.0 None | Timepoint = 12.0 hours,,,-0.55
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL5237377,Inhibition of Human CLK2 mediated phosphorylation of SRSF5 in human chondrocytes assessed by TCF/LEF reporter assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1; SM04690,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',30,nM,7.52,,,UO_0000065,14.88,0.27,1.17,6.7,0,CHEMBL5150995,Inhibition of human DYRK1A,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL2292,Dual-specificity tyrosine-phosphorylation regulated kinase 1A,Homo sapiens,SINGLE PROTEIN,CHEMBL5149981,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,30
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'>',10000,nM,,,,UO_0000065,,,,,0,CHEMBL5251373,Inhibition of recombinant human DYRK4 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL1075115,Dual specificity tyrosine-phosphorylation-regulated kinase 4,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,,,10
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1; SM04690,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,EC50,'=',20,nM,7.7,,,UO_0000065,,,,,0,CHEMBL5150993,Inhibition of Wnt signalling in human SW480 cells harbouring TCF/LEF luciferase reporter gene assessed as assessed as reduction in luciferase activity incubated for 48 hrs by Bright-Glo luciferase assay,B,BAO_0000219,cell-based format,Homo sapiens,None,None,SW480,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL5149981,1,Scientific Literature,J Med Chem,2021,None,TIME = 48.0 hr,INHIBITOR,,20
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,CL,'=',8.5,mL.min-1.kg-1,,,,,,,,,0,CHEMBL4620884,"Clearance in dog plasma at 1 mg/kg, iv",A,BAO_0000218,organism-based format,Canis lupus familiaris,CHEMBL3559721,Plasma,None,None,,,,CHEMBL612558,ADMET,,ADMET,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,0.51
CHEMBL4437054,RILEMATOVIR,3,500.93,1,3.85,53,CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,TDI,,,,,,Not Active,,,,,,0,CHEMBL4620891,Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,A,BAO_0000251,microsome format,Homo sapiens,CHEMBL3559723,Liver,None,Microsomes,,,,CHEMBL340,Cytochrome P450 3A4,Homo sapiens,SINGLE PROTEIN,CHEMBL4619758,1,Scientific Literature,J Med Chem,2020,None,,,,
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Ratio IC50,'=',12.13,,,,,,,,,,0,CHEMBL5251375,Selectivity ratio of IC50 for recombinant human CLK1 expressed in Sf9 insect cells to IC50 for recombinant human DYRK1A expressed in Sf9 insect cells,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,,,,12.13
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',76.1,nM,7.12,,,UO_0000065,14.08,0.26,0.77,6.34,0,CHEMBL5251367,Inhibition of recombinant human CLK3 expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4226,Dual specificity protein kinase CLK3,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.0761
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Ratio IC50,'=',2.36,,,,,,,,,,0,CHEMBL5251382,Selectivity ratio of IC50 for recombinant human DYRK1B expressed in Sf9 insect cells to IC50 for recombinant human DYRK1A expressed in Escherichia coli,B,BAO_0000219,cell-based format,Homo sapiens,None,None,None,None,,,,CHEMBL612545,Unchecked,,UNCHECKED,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,,,,2.36
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'>',10000,nM,,,,UO_0000065,,,,,0,CHEMBL5251364,Inhibition of recombinant human CK1epsilon expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL4937,Casein kinase I epsilon,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,,,10
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,23,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,IC50,'=',641.4,nM,6.19,,,UO_0000065,12.25,0.22,-0.16,5.52,0,CHEMBL5251374,Inhibition of recombinant human GSK-3beta expressed in Sf9 insect cells incubated for 60 mins in presence of ATP and [gamma33-P] ATP by radiometric scintillation counter analysis,B,BAO_0000219,cell-based format,Homo sapiens,None,None,Sf9,None,,,,CHEMBL262,Glycogen synthase kinase-3 beta,Homo sapiens,SINGLE PROTEIN,CHEMBL5247649,1,Scientific Literature,J Med Chem,2023,None,TIME = 1.0 hr,INHIBITOR,,0.6414
CHEMBL4297639,LORECIVIVINT,3,505.56,2,6.35,1,CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1,Inhibition,,,%,,,Active,UO_0000187,,,,,0,CHEMBL5237379,Inhibition of human CLK2 mediated phosphorylation of SRSF6 in hMSCs assessed by TCF/LEF reporter assay,B,BAO_0000357,single protein format,Homo sapiens,None,None,None,None,,,,CHEMBL4225,Dual specificity protein kinase CLK2,Homo sapiens,SINGLE PROTEIN,CHEMBL5236556,1,Scientific Literature,J Med Chem,2021,None,,INHIBITOR,,
